Praxis Precision Medicines, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$3.32 | -$0.95 | -$2.08 |
| Q2 2024 | 2 | -$3.69 | -$1.06 | -$2.31 |
| Q3 2024 | 2 | -$3.17 | -$0.91 | -$1.99 |
| Q4 2024 | 7 | -$3.00 | -$2.41 | -$2.79 |
| Q1 2025 | 5 | -$3.07 | -$2.21 | -$2.87 |
| Q2 2025 | 4 | -$4.76 | -$1.37 | -$2.99 |
| Q3 2025 | 4 | -$4.86 | -$1.40 | -$3.05 |
| Q4 2025 | 4 | -$5.06 | -$1.45 | -$3.17 |
| Q1 2026 | 3 | -$4.91 | -$1.41 | -$3.08 |
| Q2 2026 | 3 | -$5.00 | -$1.44 | -$3.14 |
| Q3 2026 | 3 | -$4.48 | -$1.28 | -$2.81 |
| Q4 2026 | 3 | -$2.90 | -$0.83 | -$1.82 |
Praxis Precision Medicines, Inc. Earnings Date And Information
Praxis Precision Medicines, Inc. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-2.75 earnings per share for the quarter, missing analysts' consensus estimates of $-2.01 by $0.74. The company had revenue of 302,000 for the quarter and had revenue of 2.45 M for the year. Praxis Precision Medicines, Inc. has generated $-19 earnings per share over the last year ($-18.69 diluted earnings per share) and currently has a price-to-earnings ratio of -8.94. Praxis Precision Medicines, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 4th, 2025 based on prior year's report dates.
Praxis Precision Medicines, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | -$2.01 | -$2.75 | -0.74 | $328,556 | $302,000 |
| 08/13/2024 | Q2 2024 | -$2.38 | -$1.74 | 0.64 | $931,222 | $357,000 |
| 05/13/2024 | Q1 2024 | -$2.01 | -$2.84 | -0.83 | $431,000 | |
| 03/05/2024 | Q4 2023 | -$3.15 | -$2.97 | 0.18 | $515,000 | |
| 11/07/2023 | Q3 2023 | -$5.25 | -$2.72 | 2.53 | $468,000 | |
| 08/09/2023 | Q2 2023 | -$9.90 | -$7.38 | 2.52 | $781,000 | |
| 05/11/2023 | Q1 2023 | -$11.24 | -$10.40 | 0.84 | $683,000 | |
| 02/07/2023 | Q4 2022 | -$10.94 | -$12.89 | -1.95 | $0 | |
| 11/09/2022 | Q3 2022 | -$13.79 | -$14.29 | -0.5 | $0 | |
| 08/08/2022 | Q2 2022 | -$19.49 | -$19.76 | -0.27 | $0 | |
| 05/09/2022 | Q1 2022 | -$19.34 | -$22.63 | -3.29 | $0 | |
| 02/28/2022 | Q4 2021 | -$16.19 | -$19.54 | -3.35 | $0 | |
| 11/03/2021 | Q3 2021 | -$13.94 | -$15.00 | -1.06 | $0 | |
| 08/16/2021 | Q2 2021 | -$10.19 | -$13.13 | -2.94 | $0 | |
| 05/11/2021 | Q1 2021 | -$11.09 | -$10.67 | 0.42 | $0 | |
| 03/17/2021 | Q4 2020 | -$5.70 | -$12.56 | -6.86 | $0 | |
| 11/23/2020 | Q3 2020 | -$0.73 | -$146.01 | -145.28 | $0 | |
| 06/29/2020 | Q2 2020 | -$105.64 | $0 | |||
| 03/30/2020 | Q1 2020 | -$76.69 | $0 | |||
| 12/30/2019 | Q4 2019 | -$68.71 | $0 |
Praxis Precision Medicines, Inc. Earnings: Frequently Asked Questions
-
When is Praxis Precision Medicines, Inc.'s earnings date?
Praxis Precision Medicines, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 4th, 2025 based off last year's report dates.
-
How can I listen to Praxis Precision Medicines, Inc.'s earnings conference call?
The conference call for Praxis Precision Medicines, Inc.'s latest earnings report can be listened to online.
-
How can I read Praxis Precision Medicines, Inc.'s conference call transcript?
The conference call transcript for Praxis Precision Medicines, Inc.'s latest earnings report can be read online.
-
How much revenue does Praxis Precision Medicines, Inc. generate each year?
Praxis Precision Medicines, Inc. (:PRAX) has a recorded annual revenue of $2.45 M.
-
How much profit does Praxis Precision Medicines, Inc. generate each year?
Praxis Precision Medicines, Inc. (:PRAX) has a recorded net income of $2.45 M. Praxis Precision Medicines, Inc. has generated $-18.69 earnings per share over the last four quarters.
-
What is Praxis Precision Medicines, Inc.'s price-to-earnings ratio?
Praxis Precision Medicines, Inc. (:PRAX) has a price-to-earnings ratio of -8.94 and price/earnings-to-growth ratio is -0.34.
